News & Updates

Use of glucagon-like peptide-1 receptor agonist (GLP-1RA) appears to reduce the risk of inflammatory bowel disease (IBD)-related surgery in patients with type 2 diabetes mellitus (T2DM) and concomitant ulcerative colitis (UC) or Crohn’s disease (CD), according to a retrospective study.

Treatment with tirzepatide significantly reduced sleep apnoea severity, as shown by a reduction in apnoea-hypopnea index (AHI), among patients with moderate-to-severe obstructive sleep apnoea (OSA) and obesity, regardless of positive airway pressure (PAP) therapy, according to two SURMOUNT-OSA trials presented at ADA 2024.

A 10-week study presented at EAN 2024 has shown that a ketogenic or “keto” diet plus regular physical exercise may be beneficial for people with narcolepsy.

New drug applications approved by US FDA as of 16-30 June 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

An intermittent fasting plan consisting of 2 nonconsecutive fasting days and 5 days of habitual intake and meal replacement diet (5:2 MR) helps keep a lid on blood sugar and promote weight loss in adults with overweight or obesity and early type 2 diabetes (T2D), according to the results of the open-label EARLY* study from China.